[Terazosine in the treatment of benign prostatic hypertrophy].
A review is presented of the current status of terazosin in the treatment of BPH. The results of many clinical trials indicate a definite and significant improvement in both subjective and objective parameters. Attention is drawn to certain possible problems and limitations of placebo controlled trials with alpha-adrenergic blockers for BPH. Parameter improvements appear to be dose-related, and the importance of dose titration is stressed. The pharmacokinetic properties of the drug enables a once daily administration. Long term treatment for more than two years indicates that efficacy is maintained.
Caine
M
M
Hadassah University Hospital Kiryat Hadassah, Jerusalem, Israël.
D000284:Administration, Oral; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D005485:Flutamide; C041226:Terazosin; D011224:Prazosin